MétaCan
Menu
Back to cohort

PD26-06 A SIGNIFICANT PROPORTION OF MEN WITH A HISTORY OF PROSTATE CANCER RECEIVING TESTOSTERONE THERAPY DO NOT RECEIVE APPROPRIATE PSA MONITORING

2020· article· en· W3021595833 on OpenAlexaboutno aff
Jason M. Scovell, Sarah McGriff, Canada Premal Patel Winnipeg, Christopher Wallis, Yonah Krakowsky, Ranjith Ramasamy

Bibliographic record

VenueThe Journal of Urology · 2020
Typearticle
Languageen
FieldMedicine
TopicHormonal and reproductive studies
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineProstate cancerTestosterone (patch)Prostate cancer screeningPopulationGynecologyCancerProstateMedical prescriptionProstate-specific antigenUrologyInternal medicineOncology

Abstract

fetched live from OpenAlex

INTRODUCTION AND OBJECTIVE: Health practitioners are hesitant to prescribe testosterone replacement therapy for men with history of prostate cancer. Emerging data suggests that testosterone therapy is safe in men with treated prostate cancer. We characterized the prescription and laboratory monitoring patterns of patients with diagnosed prostate cancer receiving testosterone therapy in a North American healthcare system. METHODS: We performed a population-based study of men aged 66 years or older +/- a history of prostate cancer that were newly treated with testosterone replacement therapy (oral, injection, gel, and patches) between the years 2008 and 2015 in Ontario, Canada using the Ontario Drug Benefit database and the Canadian Institute for Health Information. Patient age, type of therapy, practitioner type, and laboratory value data were extracted. Proportional data was evaluated using a Chi-Square test on PRISM 8 (GraphPad Software, Inc.). RESULTS: A total of 574 men with a history of prostate cancer and 14,929 men without prostate cancer all over the age of 65 received testosterone replacement therapy between 2008 and 2015. Men with a history of prostate cancer represented 4% (n=574) of total testosterone prescriptions during this time period. A greater proportion of men with a history of prostate cancer had their prostate specific antigen (PSA) checked (71%, n=410) within one year of testosterone prescription than the general population (67%, n=9,540; p<0.001); however, this rate remained inadequately low. There was no difference in PSA monitoring by age group in men with a history of prostate cancer (p=0.84). Men with a history of prostate cancer were more likely to be treated with testosterone by a Urologist compared to the general population – prostate cancer (56% GP/FP; 37% Urology; 7% Endocrinology) vs all other patients (77% GP/FP; 17% Urology; 6% Endocrinology; p<0.01). Urologists were more likely to check PSA levels (79%) in men with a history of prostate cancer on testosterone than GP/FPs and Endocrinologists (68% and 69%; p=0.03). CONCLUSIONS: Only 70% of men who receive testosterone with a history of prostate cancer have their PSA checked. Although PSA screening has witnessed a decline among general practitioners, appropriate education for testing PSA among men diagnosed with prostate cancer is critical. Source of Funding: None

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.048
Threshold uncertainty score0.095

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0010.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0120.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.039
GPT teacher head0.268
Teacher spread0.229 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueThe Journal of UrologySame topicHormonal and reproductive studiesFrench-language works237,207